Analysis of the FAH-SYSU cohort revealed that the expression level of PAX5 was higher in tumor tissues and, to some extent, could predict OS and DFS in patients with ccRCC (Additional file 5: Figure S2D). Here, PAX5 is linked to nonpapillary renal cell carcinoma.